{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T16:22:51Z","timestamp":1649089371503},"reference-count":73,"publisher":"Asia Pacific Academy of Ophthalmology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asia Pac J Ophthalmol (Phila)"],"published-print":{"date-parts":[[2019]]},"DOI":"10.22608\/apo.2018170","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T10:17:11Z","timestamp":1526379431000},"source":"Crossref","is-referenced-by-count":3,"title":["Neuromyelitis Optica: Review and Utility of Testing Aquaporin-4 Antibody in Typical Optic Neuritis"],"prefix":"10.22608","member":"9895","published-online":{"date-parts":[[2019]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/BF02224560","article-title":"Ueber das zusammenvorkommen von neuritis optica und myelitis subacuta","volume":"10","author":"Erb","year":"1880","unstructured":"1. Erb W. Ueber das zusammenvorkommen von neuritis optica und myelitis subacuta. Arch Psychiatr Neureu. 1880;10:146\u2013157.","journal-title":"Arch Psychiatr Neureu"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S0140-6736(02)68218-2","article-title":"On the ophthalmoscopic signs of spinal disease","volume":"1","author":"Allbutt","year":"1870","unstructured":"2. Allbutt T. On the ophthalmoscopic signs of spinal disease. Lancet. 1870;1: 76\u201378.","journal-title":"Lancet"},{"key":"ref2","first-page":"1033","article-title":"Myelite subaigue compliquee de neurite optique.","volume":"8","author":"Devic","year":"1894","unstructured":"3. Devic E. Myelite subaigue compliquee de neurite optique. Bull Med. 1894; 8:1033\u20131034.","journal-title":"Le Bull Medical","ISSN":"http:\/\/id.crossref.org\/issn\/0994-5636","issn-type":"print"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/0002-9394(52)90666-1","article-title":"Neuromyelitis optica","volume":"35","author":"Scot","year":"1952","unstructured":"4. Scot G. Neuromyelitis optica. Am J Ophthalmol. 1952;35:755\u2013764.","journal-title":"Am J Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1055\/s-2002-36534","article-title":"Neuromyelitis optica","volume":"22","author":"Cree","year":"2002","unstructured":"5. Cree BAC, Goodin DS, Hauser SL. Neuromyelitis optica. Semin Neurol.2002;22:105\u2013122.","journal-title":"Semin Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","unstructured":"6. Lennon PVA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106\u20132112.","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","unstructured":"7. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202:473\u2013477.","journal-title":"J Exp Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/1352458506071174","article-title":"Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica","volume":"13","author":"Watanabe","year":"2007","unstructured":"8. Watanabe S, Nakashima I, Misu T, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler J. 2007;13:128\u2013132.","journal-title":"Mult Scler J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/archneur.63.7.964","article-title":"Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression","volume":"63","author":"Pittock","year":"2006","unstructured":"9. Pittock SJ, Weinshenker BG, Lucchinetti CF, et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006;63:964\u2013968.","journal-title":"Arch Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","unstructured":"10. Roemer SF, Parisi JE, Lennon VA, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130:1194\u20131205.","journal-title":"Brain"},{"issue":"Pt 7","key":"ref10","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica.","volume":"125","author":"Lucchinetti","year":"2002","unstructured":"11. Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002;125(Pt 7):1450\u20131461.","journal-title":"Brain","ISSN":"http:\/\/id.crossref.org\/issn\/0006-8950","issn-type":"print"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","unstructured":"12. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66:630\u2013643.","journal-title":"Ann Neurol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","unstructured":"13. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009;66:617\u2013629.","journal-title":"Ann Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","unstructured":"14. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485\u20131489.","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","unstructured":"15. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177\u2013189.","journal-title":"Neurology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","unstructured":"16. Jarius S, Franciotta D, Paul F, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation. 2010;7:52.","journal-title":"J Neuroinflammation"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1212\/WNL.0000000000000114","article-title":"The two faces of neuromyelitis optica","volume":"82","author":"BG","year":"2014","unstructured":"17. Weinshenker BG, Wingerchuk DM. The two faces of neuromyelitis optica. Neurology. 2014;82:466\u2013467.","journal-title":"Neurology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e007766","DOI":"10.1136\/bmjopen-2015-007766","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis.","volume":"5","author":"Nakajima","year":"2015","unstructured":"18. Nakajima H, Motomura M, Tanaka K, et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open. 2015; 5:e007766.","journal-title":"BMJ Open","ISSN":"http:\/\/id.crossref.org\/issn\/2044-6055","issn-type":"print"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2147\/OPTH.S43894","article-title":"Visual field characteristics in neuromyelitis optica in absence of and after one episode of optic neuritis","volume":"7","author":"Merle","year":"2013","unstructured":"19. Merle H, Olindo S, Jeannin S, et al. Visual field characteristics in neuromyelitis optica in absence of and after one episode of optic neuritis. Clin Ophthalmol. 2013;7:1145\u20131153.","journal-title":"Clin Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ana.22121","article-title":"Intractable vomiting as the initial presentation of neuromyelitis optica","volume":"68","author":"Apiwattanakul","year":"2010","unstructured":"20. Apiwattanakul M, Popescu BF, Matiello M, et al. Intractable vomiting as the initial presentation of neuromyelitis optica. Ann Neurol. 2010;68: 757\u2013761.","journal-title":"Ann Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2011.03.038","article-title":"Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures","volume":"306","author":"Jarius","year":"2011","unstructured":"21. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306:82\u201390.","journal-title":"J Neurol Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","unstructured":"22. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:1\u201317.","journal-title":"J Neuroinflammation"},{"issue":"February","key":"ref22","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum.","author":"Flanagan","year":"2016","unstructured":"23. Flanagan EP, Cabre P, Weinshenker BG, et al. Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol. February 17, 2016. [Epub ahead of print].","journal-title":"Ann Neurol","ISSN":"http:\/\/id.crossref.org\/issn\/0364-5134","issn-type":"print"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","unstructured":"24. Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler. 2015;21:845\u2013853.","journal-title":"Mult Scler"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States","volume":"69","author":"Mealy","year":"2012","unstructured":"25. Mealy MA, Wingerchuk DM, Greenberg BM, et al. Epidemiology of neuromyelitis optica in the United States. Arch Neurol. 2012;69: 1176\u20131180.","journal-title":"Arch Neurol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"SJ","year":"2016","unstructured":"26. Pittock SJ, Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later. Ann N Y Acad Sci. 2016;1366:20\u201339.","journal-title":"Ann N Y Acad Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00415-009-0009-0","article-title":"An epidemiological study of neuromyelitis optica in Cuba","volume":"256","author":"Cabrera-G\u00f3mez","year":"2009","unstructured":"27. Cabrera-G\u00f3mez JA, Kurtzke JF, Gonz\u00e1lez-Quevedo A, et al. An epidemiological study of neuromyelitis optica in Cuba. J Neurol. 2009;256:35\u201344.","journal-title":"J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","unstructured":"28. H\u00f6ftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler J. 2015;21:866\u2013874.","journal-title":"Mult Scler J"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.mayocp.2016.12.014","article-title":"Neuromyelitis spectrum disorders","volume":"92","author":"BG","year":"2017","unstructured":"29. Weinshenker BG, Wingerchuk DM. Neuromyelitis spectrum disorders. Mayo Clin Proc. 2017;92:663\u2013679.","journal-title":"Mayo Clin Proc"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","unstructured":"30. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology. 2014;82:474\u2013481.","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","unstructured":"31. Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018;89:127\u2013137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS.","volume":"2","author":"Kim","year":"2015","unstructured":"32. Kim SM, Woodhall MR, Kim JS, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflammation. 2015;2:e163.","journal-title":"Neurol Neuroimmunol Neuroinflamm","ISSN":"http:\/\/id.crossref.org\/issn\/2332-7812","issn-type":"print"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","unstructured":"33. Wingerchuk DM, Pittock SJ, Lucchinetti CF, et al. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007;68: 603\u2013605.","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","unstructured":"34. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53:1107\u20131114.","journal-title":"Neurology"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ophtha.2006.06.060","article-title":"Natural history of the visual impairment of relapsing neuromyelitis optica","volume":"114","author":"Merle","year":"2007","unstructured":"35. Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology. 2007;114:810\u2013815.","journal-title":"Ophthalmology"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/archneur.61.9.1401","article-title":"The natural history of recurrent optic neuritis","volume":"61","author":"Pirko","year":"2004","unstructured":"36. Pirko I, Blauwet LK, Lesnick TG, et al. The natural history of recurrent optic neuritis. Arch Neurol. 2004;61:1401.","journal-title":"Arch Neurol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1212\/01.wnl.0000303817.82134.da","article-title":"NMO-IgG predicts the outcome of recurrent optic neuritis","volume":"70","author":"Matiello","year":"2008","unstructured":"37. Matiello M, Lennon VA, Jacob A, et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70:2197\u20132200.","journal-title":"Neurology"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/cen3.12107","article-title":"Evaluation of aquaporin-4 antibody assays","volume":"5","author":"Waters","year":"2014","unstructured":"38. Waters PJ, Pittock SJ, Bennett JL, et al. Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol. 2014;5:290\u2013303.","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1159\/000448092","article-title":"Diagnostic utility of systematic aquaporin-4 antibodies determination in the first event of immune-mediated optic neuritis","volume":"76","author":"Contentti","year":"2016","unstructured":"39. Contentti EC, De Virgiliis M, Hryb JP, et al. Diagnostic utility of systematic aquaporin-4 antibodies determination in the first event of immune-mediated optic neuritis. Eur Neurol. 2016;76:227\u2013233.","journal-title":"Eur Neurol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/jnnp.2008.146894","article-title":"Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis","volume":"81","author":"Petzold","year":"2010","unstructured":"40. Petzold A, Pittock S, Lennon V, et al. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry. 2010;81:109\u2013111.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jns.2010.07.011","article-title":"Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis","volume":"298","author":"Jarius","year":"2010","unstructured":"41. Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010; 298:158\u2013162.","journal-title":"J Neurol Sci"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","unstructured":"42. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69: 292\u2013302.","journal-title":"Ann Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00415-007-0730-5","article-title":"Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis","volume":"255","author":"Shimizu","year":"2008","unstructured":"43. Shimizu Y, Yokoyama K, Misu T, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol. 2008;255:305\u2013307.","journal-title":"J Neurol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jns.2006.10.008","article-title":"Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination","volume":"252","author":"Warabi","year":"2007","unstructured":"44. Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J Neurol Sci. 2007;252:57\u201361.","journal-title":"J Neurol Sci"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.it.2011.03.008","article-title":"Interferon-\u03b2 exacerbates Th17-mediated inflammatory disease","volume":"32","author":"Axtell","year":"2011","unstructured":"45. Axtell RC, Raman C, Steinman L. Interferon-\u03b2 exacerbates Th17-mediated inflammatory disease. Trends Immunol. 2011;32:272\u2013277.","journal-title":"Trends Immunol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000227277","article-title":"Interferon-beta(1b) treatment in neuromyelitis optica","volume":"62","author":"Tanaka","year":"2009","unstructured":"46. Tanaka M, Tanaka K, Komori M. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol. 2009;62:167\u2013170.","journal-title":"Eur Neurol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon beta treatment in neuromyelitis optica","volume":"67","author":"Palace","year":"2010","unstructured":"47. Palace J, Leite MI, Nairne A, et al. Interferon beta treatment in neuromyelitis optica. Arch Neurol. 2010;67:1016\u20131017.","journal-title":"Arch Neurol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/1352458511421185","article-title":"Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy","volume":"18","author":"Barnett","year":"2012","unstructured":"48. Barnett M, Prineas J, Buckland M, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler J. 2012;18: 108\u2013112.","journal-title":"Mult Scler J"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jns.2014.01.035","article-title":"Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab","volume":"339","author":"Kitley","year":"2014","unstructured":"49. Kitley J, Evangelou N, K\u00fcker W, et al. Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. J Neurol Sci. 2014; 339:223\u2013225.","journal-title":"J Neurol Sci"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","unstructured":"50. Kleiter I, Hellwig K, Berthele A, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012;69:239.","journal-title":"Arch Neurol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"513","DOI":"10.5692\/clinicalneurol.53.513","article-title":"[A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment]","volume":"53","author":"Izaki","year":"2013","unstructured":"51. Izaki S, Narukawa S, Kubota A, et al. [A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment]. Rinsho Shinkeigaku. 2013; 53:513\u2013517.","journal-title":"Rinsho Shinkeigaku"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","unstructured":"52. Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler J. 2012;18:113\u2013115.","journal-title":"Mult Scler J"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS)","volume":"261","author":"Trebst","year":"2014","unstructured":"53. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261:1\u201316.","journal-title":"J Neurol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1600-0404.2011.01612.x","article-title":"Treatment of steroid-unresponsive optic neuritis with plasma exchange","volume":"126","author":"Roesner","year":"2012","unstructured":"54. Roesner S, Appel R, Gbadamosi J, et al. Treatment of steroid-unresponsive optic neuritis with plasma exchange. Acta Neurol Scand. 2012; 126: 103\u2013108.","journal-title":"Acta Neurol Scand"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1212\/WNL.58.1.143","article-title":"Plasma exchange for severe attacks of CNS demyelination: predictors of response","volume":"58","author":"Keegan","year":"2002","unstructured":"55. Keegan M, Pineda AA, McClelland RL, et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002;58: 143\u2013146.","journal-title":"Neurology"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","unstructured":"56. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol. 2016;79:206\u2013216.","journal-title":"Ann Neurol"},{"issue":"October","key":"ref56","first-page":"13","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders.","author":"Bonnan","year":"2017","unstructured":"57. Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. October 13, 2017. [Epub ahead of print].","journal-title":"J Neurol Neurosurg Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0022-3050","issn-type":"print"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","unstructured":"58. Mandler RN, Ahmed W, Dencoff JE. Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology. 1998;51:1219\u20131220.","journal-title":"Neurology"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","unstructured":"59. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76:1310\u20131315.","journal-title":"Neurology"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","unstructured":"60. Cree BAC, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology. 2005;64:1270\u20131272.","journal-title":"Neurology"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","unstructured":"61. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009;66:1128\u20131133.","journal-title":"Arch Neurol"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1017\/S0317167100053932","article-title":"Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG)","volume":"31","author":"Bakker","year":"2004","unstructured":"62. Bakker J, Metz L. Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci. 2004;31:265\u2013267.","journal-title":"Can J Neurol Sci"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","unstructured":"63. Kim SH, Kim W, Park MS, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol. 2011;68: 473\u2013479.","journal-title":"Arch Neurol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2169\/internalmedicine.52.7885","article-title":"Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder","volume":"52","author":"Yaguchi","year":"2013","unstructured":"64. Yaguchi H, Sakushima K, Takahashi I, et al. Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med. 2013;52:969\u2013972.","journal-title":"Intern Med"},{"key":"ref64","first-page":"172","article-title":"Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica.","volume":"35","author":"Mok","year":"2008","unstructured":"65. Mok CC, To CH, Mak A, et al. Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica. J Rheumatol. 2008;35:172\u2013174.","journal-title":"J Rheumatol","ISSN":"http:\/\/id.crossref.org\/issn\/0315-162X","issn-type":"print"},{"issue":"February","key":"ref65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4\u2013IgG in patients in the Optic Neuritis Treatment Trial.","author":"Chen","year":"2018","unstructured":"66. Chen JJ, Tobin WO, Majed M, et al. Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4\u2013IgG in patients in the Optic Neuritis Treatment Trial. JAMA Ophthalmol. February 22, 2018. [Epub ahead of print].","journal-title":"JAMA Ophthalmol","ISSN":"http:\/\/id.crossref.org\/issn\/2168-6165","issn-type":"print"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1212\/WNL.0b013e3182563b32","article-title":"Value of NMO-IgG determination at the time of presentation as CIS","volume":"78","author":"Costa","year":"2012","unstructured":"67. Costa C, Arrambide G, Tintore M, et al. Value of NMO-IgG determination at the time of presentation as CIS. Neurology. 2012;78:1608\u20131611.","journal-title":"Neurology"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"e9193","DOI":"10.1097\/MD.0000000000009193","article-title":"Anaplastic astrocytoma with aquaporin-4 positive in CSF.","volume":"96","author":"Liu","year":"2017","unstructured":"68. Liu Y, Gao F, Hao H, et al. Anaplastic astrocytoma with aquaporin-4 positive in CSF. Medicine (Baltimore). 2017;96:e9193.","journal-title":"Medicine (Baltimore)","ISSN":"http:\/\/id.crossref.org\/issn\/0025-7974","issn-type":"print"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2377-14-139","article-title":"An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab","volume":"14","author":"S\u00e1nchez Gomar","year":"2014","unstructured":"69. S\u00e1nchez Gomar I, D\u00edaz S\u00e1nchez M, Ucl\u00e9s S\u00e1nchez AJ, et al. An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab. BMC Neurol. 2014;14: 1\u201311.","journal-title":"BMC Neurol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1177\/1352458516630823","article-title":"False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients","volume":"22","author":"Cohen","year":"2016","unstructured":"70. Cohen M, De S\u00e8ze J, Marignier R, et al. False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. Mult Scler J. 2016;22:1231\u20131234.","journal-title":"Mult Scler J"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/WNO.0000000000000509","article-title":"Advances in neuromyelitis optica: take them to the clinic","volume":"37","author":"Levin","year":"2017","unstructured":"71. Levin MH. Advances in neuromyelitis optica: take them to the clinic. J Neuro-Ophthalmology. 2017;37:300\u2013302.","journal-title":"J Neuro-Ophthalmology"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00296-014-3066-3","article-title":"Neuromyelitis optica spectrum disorders associated with other autoimmune diseases","volume":"35","author":"Freitas","year":"2015","unstructured":"72. Freitas E, Guimar\u00e3es J. Neuromyelitis optica spectrum disorders associated with other autoimmune diseases. Rheumatol Int. 2015;35:243\u2013253.","journal-title":"Rheumatol Int"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non-organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","unstructured":"73. Pittock SJ, Lennon VA, de Seze J, et al. Neuromyelitis optica and non\u2013organ-specific autoimmunity. Arch Neurol. 2008;65:78\u201383.","journal-title":"Arch Neurol"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"deposited":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:05:16Z","timestamp":1561766716000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/apjoo\/Fulltext\/2018\/07000\/Neuromyelitis_Optica__Review_and_Utility_of.3.aspx"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":73,"URL":"https:\/\/doi.org\/10.22608\/apo.2018170","relation":{},"ISSN":["2162-0989","2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"},{"value":"2162-0989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}